PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32246989-5	2020	Moderate or strong staining for VEGF on TCs was found in 217 (42.3%) patients.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	40-43	vascular endothelial growth factor A	Homo sapiens	32-36	
32998161-11	2020	In presence of IL-1beta, TCs showed an upregulation of ADORA2A, SCX and COL3A1 expression and an increase of IL-6, IL-8, PGE2 and VEGF secretion.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	25-28	vascular endothelial growth factor A	Homo sapiens	130-134	
31522559-10	2019	Inhibition of VEGF reversed the effects of miR-146a inhibitor on TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	65-68	vascular endothelial growth factor A	Homo sapiens	14-18	
31522559-13	2019	Altogether, the results suggest that miR-146a modulated TCs" tumor formation and invasion and was associated with VEGF/CDC42/PAK1 signaling.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	56-59	vascular endothelial growth factor A	Homo sapiens	114-118	
21182812-7	2006	Both in TCs and FBs, the positive expression of VEGF, KDR and Flt1 was related to the postoperative survival of patients (P < 0.01, P < 0.01, P < 0.01; P < 0.01, P < 0.01, P < 0.05).	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	8-11	vascular endothelial growth factor A	Homo sapiens	48-52	
21182812-8	2006	The survival time in patients with positive VEGF, KDR or Flt-1 in TCs was significantly lower than that in those with corresponding negative one respectively (P < 0.0001, P < 0.0005, P < 0.0005).	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	66-69	vascular endothelial growth factor A	Homo sapiens	44-48	
15708122-16	2005	CONCLUSION: We concluded that upregulation of sFlt-1 and unbalanced PlGF/VEGF production associated with increased oxidative stress are consequences of hypoxia in placental TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	173-176	vascular endothelial growth factor A	Homo sapiens	73-77	
15708122-17	2005	Our results suggest that placental TCs are major sources of sFlt-1 and VEGF levels in the maternal circulation in women with preeclampsia.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	35-38	vascular endothelial growth factor A	Homo sapiens	71-75	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	93-96	vascular endothelial growth factor A	Homo sapiens	102-136	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	93-96	vascular endothelial growth factor A	Homo sapiens	138-142	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	156-159	vascular endothelial growth factor A	Homo sapiens	102-136	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	156-159	vascular endothelial growth factor A	Homo sapiens	138-142	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	156-159	vascular endothelial growth factor A	Homo sapiens	102-136	
33913456-8	2021	Key characteristics of T cell dynamics in tumor microenvironments are recapitulated in the MBTCs: the vascular endothelial growth factor (VEGF) produced by TCs suppressed EC activation by inflammatory cytokines, or induced EC anergy, thereby significantly reducing T cell extravasation, whereas chemokines produced by TCs triggered T cell chemotaxis toward TCs.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	156-159	vascular endothelial growth factor A	Homo sapiens	138-142